AK131

DRUG2 trials

Sponsors

Fudan University, Akeso

Conditions

Solid TumorTriple-negative Breast Cancer

Phase 1

A Study of AK131 in Patients With Advanced Solid Tumors

RecruitingNCT06166888

AkesoSolid Tumor

Start: 2024-01-10End: 2028-12-31Target: 130Updated: 2024-01-17

Phase 2

Reverse Triple Negative Immune Resistant Breast Cancer

RecruitingNCT05076682

Fudan UniversityTriple-negative Breast Cancer

Start: 2022-06-30End: 2027-03-31Target: 80Updated: 2025-12-03

Related Papers

Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial.

2025-06-25

Abstract PO1-14-07: Programme of mast cell subsets to potentiate breast cancer immunotherapy: from bed to bench to bed (the phase 2 platform RENAISSANCE trial)

Cancer Research2024-05-02